Company Overview of FORMA Therapeutics, Inc.
FORMA Therapeutics, Inc. discovers and develops medicines for cancer and other genetically-driven diseases. The company’s drug discovery engine deploys screening and structure-based approaches across various families of targets involved in tumor metabolism, epigenetics, protein homeostasis, and protein-protein interactions. It has a strategic partnership with Celgene Corporation. FORMA Therapeutics, Inc. was formerly known as Forma Pharmaceuticals, Inc. and changed its name to FORMA Therapeutics, Inc. in February 2008. The company was incorporated in 2007 and is based in Watertown, Massachusetts. The company has an additional chemistry operation in Branford, Connecticut. FORMA Therapeutics, ...
500 Arsenal Street
Watertown, MA 02472
Founded in 2007
Key Executives for FORMA Therapeutics, Inc.
Co-Founder, Chief Executive Officer, President and Director
Chief Intellectual Property Counsel and Vice President of Legal
Head of Biomolecular Screening and Executive Director
Compensation as of Fiscal Year 2016.
FORMA Therapeutics, Inc. Key Developments
FORMA Therapeutics, Inc. Appoints Jim Winkler as Vice President, Discovery and Translational Biology
Oct 11 16
FORMA Therapeutics, Inc. announced the appointment of Jim Winkler, Ph.D., as Vice President, Discovery and Translational Biology. Dr. Winkler joins the FORMA leadership team with over 30 years’ experience in the biotechnology and pharmaceutical industry within oncology and inflammation, and most recently served as Chief Scientific Officer at Arvinas, Inc., in New Haven, Connecticut.
FORMA Therapeutics, Inc. Appoints Karoline Shair as Vice President, Legal and Chief Intellectual Property Counsel
Aug 29 16
FORMA Therapeutics, Inc. announced the appointment of Karoline Shair, Ph.D., J.D., as Vice President, Legal and Chief Intellectual Property Counsel. Karoline joins the FORMA leadership team with over 20 years’ global experience in the biotechnology and pharmaceutical sector. She most recently served as Vice President and IP Region Head, at Takeda Pharmaceuticals International Co., in Cambridge, Massachusetts.
FORMA Therapeutics Enrolls First Patient in Phase 1 Study of FT-1101 in Advanced Hematological Malignancies
Jan 12 16
FORMA Therapeutics announced the initiation of a Phase 1 study of FT-1101, with the first dose administration in patients with relapsed/refractory acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome. FT-1101 is an oral, structurally distinct and potent pan-inhibitor of the BET (Bromodomain and Extra-Terminal) epigenetic protein family. Small molecule inhibition of BET results in down-regulation of the critical oncogene MYC, a master regulator of diverse cell functions critical for cell growth and survival in many cancers. At tolerated doses in human tumor xenograft mousemodels, FT-1101 has demonstrated significant anti-tumor activity including tumor regressions. FT-1101 is part of FORMA’s second global strategic collaboration with Celgene Corporation announced in April 2014. Celgene has obtained an exclusive EU license for FT-1101 in exchange for an undisclosed payment to FORMA. Under the terms of the collaboration agreement, FORMA will advance the FT-1101 program through Phase 1, and Celgene will be responsible to fund and execute further global clinical development. The Phase 1 multicenter, open-label, dose escalation clinical trial is designed to assess the safety and tolerability of FT-1101 capsules as a single agent. FT-1101 will be administered orally on a once weekly dosing schedule in a 28-day cycle. The study will enroll patients with relapsed refractory AML and high risk myelodysplastic syndrome. Key objectives in the study include determination of a maximum tolerated dose, pharmacokinetics, pharmacodynamics and preliminary anti-tumor activity of FT-1101.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|